Farallon owns more than 2.3 million shares of Pharmion

By Lisa Kerner

Charlotte, N.C., Feb. 1 - Farallon Capital Partners, LP reported a 6.2% stake in Pharmion Corp. after a series of stock transactions between Dec. 10 and Jan. 29.

The investors beneficially own 2,318,555 shares of the Boulder, Colo., oncology company's common stock.

On Nov. 19, it was announced that Celgene Corp. agreed to acquire Pharmion for $72.00 per share in a cash and stock transaction valued at $2.9 billion.

As previously reported, under the merger agreement, each share of Pharmion common stock will be exchanged for $25.00 in cash plus shares of Celgene common stock in an amount to be determined by an exchange ratio.

Celgene is a Summit, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.